Irinotecan: all 829 studies that test it
Page 1 of 9. Open to participants first (121), then studies with results posted, then the rest; newest registration first within each.
- Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.Not yet recruitingNCT07853105Phase 1/2
- VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent GliomaRecruitingNCT07831369Phase 2
- Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant MelanomaNot yet recruitingNCT07817901Phase 1/2
- Liposomal Irinotecan Plus Cisplatin in Patients With Advanced or Metastatic Solid MalignanciesNot yet recruitingNCT07782346Phase 1
- SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC TrialNot yet recruitingNCT07748611Phase 2
- DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic CancerRecruitingNCT07705919Phase 1/2
- Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingNCT07591831Phase 2
- Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver MetastasesNot yet recruitingNCT07570914Phase 2
- SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After ImmunotherapyNot yet recruitingNCT07524374Phase 2
- Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal CancerNot yet recruitingNCT07521605Phase 2
- Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic OsteosarcomaRecruitingNCT07479732Phase 1/2
- SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARCRecruitingNCT07474103Not applicable
- A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesRecruitingNCT07415031Phase 2
- Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard TherapyRecruitingNCT07397819Phase 1/2
- ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"RecruitingNCT07381764Phase 2
- Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and GanglioneuroblastomaRecruitingNCT07375563Phase 3
- Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPSRecruitingNCT07328425Phase 2
- NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic CancerNot yet recruitingNCT07314385Phase 1
- A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E MutationNot yet recruitingNCT07229846Phase 2
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesRecruitingNCT07194044Phase 1
- Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)RecruitingNCT07155200Phase 1/2
- An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular TypingNot yet recruitingNCT07141771Phase 1/2
- Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic AdenocarcinomaRecruitingNCT07076212Phase 2
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingNCT07070479Phase 2
- Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal CancerNot yet recruitingNCT07051785Phase 2
- PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer TreatmentNot yet recruitingNCT07028424Phase 2
- Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory NeuroblastomaRecruitingNCT07027748Phase 1
- A Irinotecan Liposome Trial of in Advanced Neuroendocrine CarcinomaNot yet recruitingNCT07014540Phase 4
- Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.RecruitingNCT06894797Not applicable
- Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.Not yet recruitingNCT06888648Phase 1/2
- Study of NALIRIFOX in Advanced Unresectable Small Bowel TumorsRecruitingNCT06835387Phase 2
- Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing SarcomaRecruitingNCT06827717Phase 2
- NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar TrialRecruitingNCT06821997Phase 2
- UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid TumorsRecruitingNCT06760117Phase 1
- DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic CancerRecruitingNCT06757244Phase 2
- Liposomal Irinotecan and Apatinib in ES-SCLCRecruitingNCT06749691Phase 2
- Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic CancerNot yet recruitingNCT06700603Phase 2
- Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTCNot yet recruitingNCT06699459Phase 2
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
- Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPCRecruitingNCT06657690Phase 2
- CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRCNot yet recruitingNCT06652412Phase 2
- Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic CancerNot yet recruitingNCT06571461Phase 3
- Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer StudyRecruitingNCT06547203Phase 2
- N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With NeuroblastomaRecruitingNCT06528496Phase 2
- Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.RecruitingNCT06514313Phase 2
- Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic CancerNot yet recruitingNCT06513455Phase 1/2
- A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06512428Phase 2
- Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCCNot yet recruitingNCT06501664Phase 3
- Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric CancerNot yet recruitingNCT06499610Phase 4
- Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLCRecruitingNCT06496048Phase 3
- Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06491134Phase 1
- The Sagittarius TrialRecruitingNCT06490536Phase 3
- Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung CancerRecruitingNCT06467786Phase 4
- NALIRIFOX as Induction Therapy in LAPCRecruitingNCT06467565Phase 2
- NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) TrialRecruitingNCT06450041Phase 2
- Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric CancerNot yet recruitingNCT06437678Phase 2
- Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal CancerNot yet recruitingNCT06434090Phase 1/2
- NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDACRecruitingNCT06405490Phase 2
- Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal CancerRecruitingNCT06405139Phase 2
- A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)RecruitingNCT06401330Phase 3
- Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic CancerRecruitingNCT06361316Not applicable
- NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory StudyRecruitingNCT06345300Phase 2
- Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing SarcomaRecruitingNCT06340204Phase 1
- Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With ImmunotherapyNot yet recruitingNCT06332950Phase 1/2
- ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRCRecruitingNCT06321081Phase 2
- Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLCRecruitingNCT06258642Not applicable
- Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal CancerRecruitingNCT06225622Phase 1
- Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOXNot yet recruitingNCT06210360Phase 2
- Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent CancerRecruitingNCT06208657Phase 1/2
- Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric CancerNot yet recruitingNCT06197438Phase 2
- Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal CancerNot yet recruitingNCT06192680Phase 2
- Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal CancerRecruitingNCT06184698Phase 2
- Study of LY01610 in Patients With Recurrent Small Cell Lung CancerRecruitingNCT06128837Phase 3
- Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk DiseaseRecruitingNCT06023641Phase 2
- A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid TumorsRecruitingNCT06006273Phase 1
- Intraperitoneal Irinotecan With Concomitant FOLFOX and BevacizumabRecruitingNCT06003998Phase 2
- A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerRecruitingNCT05999994Phase 2
- Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line TherapyRecruitingNCT05962502Phase 2
- Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .RecruitingNCT05927857Phase 1/2
- Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal CancerRecruitingNCT05806931Phase 2
- Dose Attenuated Chemotherapy in Compromised Patients With Lung CancerRecruitingNCT05800587Phase 2
- Combination Therapy in Cancers With Mutations in DNA Repair GenesRecruitingNCT05694715Phase 1
- Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric CancerNot yet recruitingNCT05669807Phase 2
- AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular CarcinomaRecruitingNCT05669339Phase 2
- Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric CancerNot yet recruitingNCT05643677Phase 2
- Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung CancerNot yet recruitingNCT05595889Phase 2
- Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical StudyRecruitingNCT05457829Phase 2
- GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant AscitesRecruitingNCT05438459Phase 1/2
- SMART TNT for the Conservative Management of Locally Advanced Rectal CancerRecruitingNCT05412082Phase 1
- GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual CareRecruitingNCT05391126Not applicable
- Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NETEnrolling by invitationNCT05385861Phase 1/2
- Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)RecruitingNCT05384821Phase 1/2
- Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AIRecruitingNCT05381038Phase 1/2
- Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic AdenocarcinomaRecruitingNCT05363007Phase 2
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingNCT05319730Phase 1/2
- Phase I/II Study of the Combination of Irinotecan and POF (POFI) and TislelizumabRecruitingNCT05319639Phase 1/2
- Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRCRecruitingNCT05229003Phase 2
- SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal CancerRecruitingNCT05160896Phase 2
- ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver MetastasesRecruitingNCT05062317Phase 2
- Efficacy of Hyperthermic Intraperitoneal ChemotherapyRecruitingNCT04861558Phase 3